Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Sweden
/
Healthcare
/
Vimian Group
VIMIAN
Vimian Group
Rising Interest Rates And Tariffs Will Weaken US MedTech Margins
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
10 Jul 25
Updated
16 Jul 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
SEK 37.32
13.1% undervalued
intrinsic discount
16 Jul
SEK 32.44
Loading
1Y
-2.3%
7D
-2.9%
Author's Valuation
SEK 37.3
13.1% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
SEK 37.3
13.1% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-14m
537m
2018
2020
2022
2024
2025
2026
2028
Revenue €537.0m
Earnings €90.3m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
9.47%
Medical Equipment revenue growth rate
0.32%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
5.95%
Calculation
€90.25m
Earnings '28
x
22.96x
PE Ratio '28
=
€2.07b
Market Cap '28
€2.07b
Market Cap '28
/
528.33m
No. shares '28
=
€3.92
Share Price '28
€3.92
Share Price '28
Discounted to 2025 @ 5.79% p.a.
=
€3.31
Fair Value '25
€3.31
Fair Value '25
Converted to SEK @ 11.3052 EUR/SEK Exchange Rate
=
SEK 37.42
Fair Value '25